Allostera owns under its license agreement with Univalor, a patent portfolio of 25 worldwide patent applications in eight different families including patents covering the Module X process as well as broad composition of matter of the products in its pipeline.

To date, one US patent, #7,432,341 has been issued covering its VEGFR Allosteramers™.

All of Allostera’s technologies to date, including intellectual properties developed in the laboratories of Sylvain Chemtob and Christiane Quiniou, the co-founders of Allostera, have been broadly in-licensed from the CHU Ste-Justine and University of Montreal via separate corporate entities formed for this purpose.